Yita Lee & Muh-Hwan Su of Sinphar Group & SynCore Bio describe the exciting R&D projects of SynCore Bio, the oncology & dry AMD focused innovation-driven company of the group, and the advantages of SynCore Bio’s integration within Sinphar Group.
As an introduction to our international readers, could you provide us with an overview of Sinphar Group and explain its positioning within the Taiwanese pharmaceutical landscape?
"Although Sinphar has been historically focused on generics, our Chairman has been steadily steering the direction of our group toward a more R&D-driven approach for already two decades."
